Expression of P-gp, MRP, LRP, GST-π and Topoiiα and acquired resistance to cisplatin in human lung adenocarcinoma cells

Jiarui Wang, Zhongzhou He, Lichuan Zhang, Encheng Li, Qiang Meng, Lijuan Zou, Joseph Molnár, Qi Wang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

This study aimed at analyzing the relationship between the expression of P-gp, MRP, LRP, GST-π and TopoIIα and acquired resistance to cisplatin in lung adenocarcinoma cell line A549. Drug resistance to cisplatin was determined using MTT assays. The expressions of P-gp, MRP, LRP, GST-π and TopoIIα were measured by immunofluorescence, Western blot and RT-PCR. The results showed that there was a significant elevation of IC50 of cisplatin in A549/DDP cells compared to A549 cells (73.95 ± 7.26 versus 7.28 ± 0.74). The expression of P-gp and MRP in A549/DDP cells was approximately 1.5-fold higher than that in A549 cells (61.99±2.63 versus 43.52±1.22;34.11±2.17 versus 22.80±2.31 respectively), whereas TopoIIα expression was about 3-fold lower in A549/DDP cells than that in A549 cells (0.34±0.06 versus 0.92±0.03). In conclusion, acquired resistance to cisplatin was associated with the up-regulation of P-gp and MRP and the down-regulation of TopoIIα in human lung adenocarcinoma cell line A549.

Original languageEnglish
Pages (from-to)148-153
Number of pages6
JournalLetters in Drug Design and Discovery
Volume8
Issue number2
DOIs
Publication statusPublished - Feb 1 2011

Keywords

  • Acquired resistance
  • Cisplatin
  • GST-π
  • LRP
  • Lung cancer
  • MRP
  • P-gp
  • TopoIIα

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Fingerprint Dive into the research topics of 'Expression of P-gp, MRP, LRP, GST-π and Topoiiα and acquired resistance to cisplatin in human lung adenocarcinoma cells'. Together they form a unique fingerprint.

  • Cite this